secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0000875320-25-000171
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q1 revenue $2.77B (+3% YoY); GAAP net income falls to $646M on $379M impairment; FY guidance raised
--------------------------------------------------------------------------------

- Revenue $2.77B, +3% YoY; US revenue +9% to $1.66B, ex-US -5% to $1.11B due to Russia IP violation.
- GAAP net income $646M vs $1.1B Q1 2024; includes $379M impairment charge on discontinued VX-264 T1D program.
- Non-GAAP net income $1.1B vs $1.2B; combined non-GAAP R&D, AIPR&D and SG&A expenses $1.2B.
- Raised FY2025 revenue guidance low end to $11.85B-$12B (from $11.75B-$12B); reiterates expense guidance.
- JOURNAVX launch: >20,000 prescriptions filled since March; ~94M lives have covered access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532025000171/0000875320-25-000171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532025000171/vrtx-20250505.htm
  HTML page:      https://secwatch.observer/filing/0000875320-25-000171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer